PubMed Health⌕ Search

PubMed · 9713194

[Phacotopic glaucoma].

Abstract

Phacotopic glaucomas or hypertonias due to lens movements are not rarely in ophthalmology. They are often due to a traumatic pathology. They are seldom due to a congenital or acquired zonular disease. It is very important to recognize the pathogenic mechanism for a proper treatment: pupillary block and/or angular block or phacolytic glaucoma. Lens displacement is possible in three different places, that may lead to different causes of hypertonia, that need different treatments. Laser iridotomy, improvement of lens and vitreous surgery changed the prognosis of this diseases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D P Popa, F Grigoriu. 1998. [Phacotopic glaucoma].. https://pubmed.health/record/pubmed%3A9713194/phacotopic-glaucoma

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

Screening for prevention of optic nerve damage due to chronic open angle glaucoma.

BACKGROUND: Open angle glaucoma (OAG) is a primary, progressive optic neuropathy; the onset is without symptoms and progression occurs silently until the advanced stages of the disease, when it affects central vision. The blindness caused by OAG is irreversible. It has often been assumed to be a condition that fulfils the criteria for population screening, although this has not been supported by other in-depth non-systematic reviews. The focus of this review was to examine the evidence for the effectiveness of screening for OAG. OBJECTIVES: To determine the impact of screening for OAG compared with opportunistic case findings or current referral practices on the prevalence of and the degree of optic nerve damage due to OAG in screened and unscreened populations. SEARCH STRATEGY: We included any randomised controlled trial (RCT) evaluating population-based screening programmes for OAG with a minimum one year follow up. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (which contains the Cochrane Eyes and Vision Trials Register) (Issue 1, 2006), MEDLINE (1950 to February 2006) and EMBASE (1988 to February 2006). We also searched the National Research Register (Issue 1, 2006) and Zetoc for grey literature (29 June 2006). There were no language or date restrictions in the electronic searches. SELECTION CRITERIA: We planned to include RCTs, including cluster RCTs. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed the study abstracts identified by the electronic searches. We did not find any trials that met the inclusion criteria. MAIN RESULTS: As no trials were identified, no formal analysis was performed. AUTHORS' CONCLUSIONS: On the basis of current evidence, population-based screening for chronic OAG cannot be recommended, although much can be done to improve awareness and encourage at risk individuals to seek testing. In wealthy countries with equitable access to high quality eye care and health education, blindness from chronic OAG should become increasingly rare; much greater challenges face poor and emerging economies and countries where there are substantial health and wealth inequalities. Effectiveness of screening for OAG can be established only by high quality RCTs.

Glaucoma, Open-Angle↗

Chase the family.

Explore the source record for details and available documents.

Glaucoma, Open-Angle↗